CLASS II ONGOING Drug recall · Reported 5 Dec 2018 · FDA Enforcement Report

Losartan Potassium and Hydrochlorothiazide Tablets, USP 100 mg/25 mg recalled

Sandoz is recalling Losartan Potassium and Hydrochlorothiazide Tablets, USP 100 mg/25 mg, distributed in Ohio, Puerto Rico. The recall was initiated on 1 Nov 2018 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot #: JB8912; Exp. 06/2020
Quantity recalled170 HDPE bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0359-2019
FDA event ID
81485
Recalling firm
Sandoz, Princeton, NJ
Classification
Class II
Status
Ongoing
Recall initiated
1 Nov 2018
FDA classified
14 Jan 2019
Reported
5 Dec 2018
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Nitrosamine Impurity

Timeline

1 Nov 2018Recall initiated by company
5 Dec 2018Published in enforcement report+34 days
14 Jan 2019Classified by FDA+40 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.

Nitrosamines are impurities that can form during drug manufacturing or storage. Above the FDA acceptable intake limit, long-term exposure may raise cancer risk. The FDA advises patients to keep taking the medicine until they have a replacement.

Product as listed by the FDA

Sandoz Losartan Potassium and Hydrochlorothiazide Tablets, USP 100 mg/25 mg, 1000-count bottles, Rx Only, Finished Drug Product Manufactured by: Lek Pharmaceuticals d.d. SI-1526 Ljubljana,Sovenia for Sandoz Inc., Princeton, NJ 08540, NDC 0781-5207-10.

Where it was distributed

OH, PR

OhioPuerto Rico

Questions about this recall

Why was it recalled?

CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.

Which lots are affected?

Lot #: JB8912; Exp. 06/2020

Where was it sold?

OH, PR

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Sandoz

All 59

Other Losartan recalls

All 97
ReportedClassRecallCompanyReasonWhere
DrugCLASS IILosartan Potassium and Hydrochlorothiazide Tablets recalledLosartan Potassium And HydrochlorothiazideMacleods Pharma USAForeign MaterialNationwide
DrugCLASS IILosartan Potassium Tablets, USP, 25 mg recalled by Strides PharmaLosartan PotassiumStrides PharmaForeign MaterialNationwide
DrugCLASS IILosartan potassium & Hydrochlorothiazide Tablets 100 mg/25 recalledLosartan Potassium And HydrochlorothiazideMacleods Pharma UsaPotency & AssayNationwide
DrugCLASS IILosartan Potassium Tablets, USP 25 mg recalled by PD-Rx PharmaceuticalsLosartan PotassiumPD-Rx PharmaceuticalsPotency & AssayNationwide
DrugCLASS IILosartan Potassium Tablets, USP 100 mg recalled by PD-Rx PharmaceuticalsLosartan PotassiumPD-Rx PharmaceuticalsPotency & AssayNationwide